Dr. Rojas is a diplomate of the American Board of Obesity Medicine and is specialized in medical weight management. Dr. Rojas offers customized Weight loss Management in Chicago, IL plans that include, lifestyle changes, nutritional consulting, and pharmacological treatment options.
Ask about our Lifestyle plan and other pharmacological options for weight loss including metformin, semaglutide and others to help you achieve success in your weight management journey. Dr. Rojas offers weight management treatment options including medications, including, Semaglutide an FDA-approved weight loss treatment. Semaglutide also effectively treats people with type 2 diabetes to improve blood sugar control. Semaglutide has a similar structure to the hormone glucagon-like peptide-1 (GLP-1). When we eat, GLP-1 is released, increasing insulin release, which helps regulate blood sugar levels. As a food intake and appetite regulator, semaglutide mimics the hormone GLP-1. By doing this, you will feel full sooner which will help you eat less and lose weight.
Semaglutide, also known by the brands Rybelsus®, Ozempic®, and Wegovy®, helps control blood sugar levels in people with type 2 diabetes and encourages weight loss when combined with an exercise program. Semaglutide is a glucagon-like peptide-1 agonist that lowers blood sugar levels, reduces appetite, slows the gastrointestinal tract, and makes you feel full after eating.
Semaglutide stays in your body for up to five weeks after your last dose.
Semaglutide Weight Loss Injection in Chicago, Illinois is believed to be able to decrease appetite. Furthermore, by slowing gastric emptying, GLP-1 increases your feeling of fullness for longer and directly influences appetite regulation.
The full effects of Semaglutide for diabetes may not be noticed for eight weeks. The time frame shifts if you take weekly GLP-1 receptor agonist injections for weight loss.
Schedule Your Consultation Today.
We Have Answers! Send Us A Message.
© 2024 Beautyatfirstsight. All Rights Reserved
Site Developed And Maintained By:
